2021-05-29| Asia-PacificR&D

HitGen Partners with Dorian to develop DNA-Encoded Library-Based Anti-Aging Drugs

by Kathy Huang
Share To

Jin Li, Chairman & CEO of HitGen Image source:

China-based pharmaceutical company HitGen has announced a research collaboration with Dorian Therapeutics on May 24th. Under the agreement, HitGen will receive an undisclosed upfront payment from Dorian.

HitGen, renowned for its DNA-encoded libraries (DEL) in early drug discovery and is profited by it. DEL enables the synthesis and screening of unprecedented chemicals more efficiently, and it is now available for over 1 trillion DNA-encoded compounds. The collaboration with Dorian shows HitGen’s ambition to expand its pharmaceutical business in age-related diseases.


Senoblockers – Treatments Enhancing Regenerative Capacity of Aging cells

Senoblockers are treatments for aging diseases developed by Dorian. They act on aged tissues to reactivate the generation of cells, which provide therapeutics for aging diseases like Alzheimer’s, osteoporosis, and autoimmune diseases. HitGen will apply its platform technology to those disease targets senoblockers treat for.


Previous Collaborations

On April 6th, HitGen signed a drug discovery collaboration with BioAge, a company specializing in building biobanks that identify drug targets of elderly diseases. The partnership with BioAge and Dorian has the potential for HitGen to open up markets on age-associated diseases.

“We look forward to working with Dorian to identify novel small molecule starting points from DNA-encoded libraries,” Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen said, “We will work closely with Dorian scientists to generate new lead compounds for their research programs to address unmet medical needs associated with aging.”

Related Article: AstraZeneca, Geneseeq Sign Collaborative Deal to Build Bio Center in China


© All rights reserved. Collaborate with us:
Related Post
Discrimination Leads to Rapid Aging, Science Shows the Detrimental Effects of this Act
Inside the Aging Brain: NTU Singapore’s Revelation on Memory Neuron Communication
BioFuture NYC 2022: Using Technology to Prepare for an Aging Population
Taiwan Biotech Delegation Leads International Exchange with Phoenix Biotech Community and Mayo Clinic
BIO 2024 Sets the Stage for Taiwan’s Biotech Industry to Shine
GV Innovation High-Value Niche Market Transformation Project
ASCO 2024: Covering Skin Cancer, Bispecific Antibody Treatment, TIGIT-Targeted Drugs, Radiotherapy and More
Major Cancer Research Publications at the 2024 American Society of Clinical Oncology Annual Meeting
Eli Lilly Breaks Records with $9B Total Investment in Indiana Weight-loss Drug Expansion
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
Scroll to Top